​​​
  1. Aurobindo Q3 net profit up a tad

Aurobindo Q3 net profit up a tad

Formulation sales in the US registered Rs 1,909.6 crore, compared with Rs 1,745.1 crore in Q3FY17, a growth of 9.4%. The Europe formulation sales stood at Rs 1,171.6 crore, registering a strong growth of 37% on a year-on-year basis.

By: | Hyderabad | Published: February 8, 2018 5:19 AM
Aurobindo Pharma reported a marginal increase of 3% in its net profit to Rs 595 crore for the third quarter, against Rs 578.6 crore in the year-ago period.

Aurobindo Pharma reported a marginal increase of 3% in its net profit to Rs 595 crore for the third quarter, against Rs  578.6 crore in the year-ago period. Revenue from operations stood at Rs 4,336.1 crore, an increase of 11% over the same period last year. Formulation sales in the US registered Rs 1,909.6 crore, compared with Rs 1,745.1 crore in Q3FY17, a growth of 9.4%. The Europe formulation sales stood at Rs 1,171.6 crore, registering a strong growth of 37% on a year-on-year basis. “All our key markets continue to perform well and have shown a healthy growth trend. Considering the one-off US tax charge, the profitability is in-line with our expectations. We continue to invest in enhancing our specialty and complex generics pipeline, for a sustainable growth,” N Govindarajan, MD, said in a statement. While the anti-retro viral (ARV) sales registered Rs 238.9 crore, against Rs 341.9 crore in Q3FY17, the growth market sales was at Rs 250.2, up 33.2%. API sales for thee quarter stood at Rs 765.7 crore, compared with Rs 775.9 crore.

Get live Stock Prices from BSE and NSE and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

  1. No Comments.

Go to Top